General Information of This Drug (ID: DMYK8MV)

Drug Name
Melanotetan II   DMYK8MV
Synonyms
Monorden; UNII-I60EH8GECX; I60EH8GECX; CHEMBL414883; CHEBI:556075; (1aR,2Z,4E,14R,15aR)-8-chloro-9,11-dihydroxy-14-methyl-1a,14,15,15a-tetrahydro-6H-oxireno[e][2]benzoxacyclotetradecine-6,12(7H)-dione; Monorderne; RDC; C18H17ClO6; Radisicol; Radicolol; Monorden A; RHI-12648; Microlactone, 1; 3cgy; NSC-294404; 4egk; 2wer; NSC 294404; 2zbk; 1bgq; (+)-Monorden A; Radicicol R 2146; 2q8i; SCHEMBL868832; BDBM15361; MolPort-003-959-447; HMS3648C16; BDBM227589; 6H-Oxireno(e)(2)benzoxacyclotetradecin-6,12(7H)-dione, 8-chlor
Drug Type
Small molecular drug

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Preclinical Indication(s)
Indication Name Indication ID ICD-11 Status REF
Type-2 diabetes DIS3X247 5A11 Preclinical [1]
Obesity DIS47Y1K 5B81 Preclinical [1]
Sexual dysfunction DIS7WG2P HA00-HA01 Preclinical [1]
------------------------------------------------------------------------------------

References

1 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.